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Abbreviation 
    OHAs: Oral Hypoglycemic Agents; ASCVD: Atherosclerotic Cardiovascular Disease; GLP-1 RA: Glucagon-Like 




Background: Recent diabetic treatments include Insulin Degludec/liraglutide (IDeg/Lira, Xultophy) in 
clinical practice. Authors have continued clinical research concerning diabetes, chronic renal failure, dialysis, 
and others. 
Subjects and Methods: Ten patients with type 2 diabetes mellitus (T2DM) undergoing hemodialysis were 
investigated. They showed that ages 74.5 ± 5.9 years, M/F=6/4, BMI 21.1± 3.8kg/m2, hemodialysis duration 
8.1± 5.7 years. At the beginning, fundamental data were Cre 8.2 ± 1.9 mg/dL, HbA1c 6.5 ± 0.8%. Xultophy 
was started on 5-12 doses and continued for 6 months with the same or 1-4 increased doses for better 
glycemic variability. 
Results: Out of 10 subjects, the changes in HbA1c showed a decrease in 7, stable in 2, and an increase in 1. 
HbA1c value was 6.2 ± 0.8% in average at 6 months. There were no remarkable adverse effects by Xultophy 
for 6 months. 
Discussion and Conclusion: Xultophy was started at 5-12 doses, which were remarkably lower doses than 
usual doses with satisfactory efficacy. One of the reasons may be from the characteristic of the patients, who 
were diabetic with undergoing hemodialysis. Another factor is possibly from liraglutide, which has hepatic 
clearance with potential vascular protective effects. These results are expected to become reference data for 
future research. 
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Introduction 
    As to the fundamental therapy for T2DM, 
comprehensive lifestyle changes such as meal, weight 
control, and exercise remain as first-line treatment. 
However, most patients require dual or triple oral 
hypoglycemic agents (OHAs) to keep adequate glucose 
variability [1,2]. There are some main guidelines 
concerning diabetic management, such as the 2019 
consensus report of the European Association for the 
Study of Diabetes (EASD) and the American Diabetes 
Association (ADA), and 2020 ADA guidelines. They 
recommend the stepwise addition of several kinds of 
agents for diabetes. In such cases, some aspects should 
be considered, including drug characteristics, 
administration route, costs, adverse effects, patient 
preference, as well as present comorbidities such as 
heart failure (HF), atherosclerotic cardiovascular 
disease (ASCVD), and chronic kidney disease (CKD) 
[1,2].  
 
    Co-administration of a glucagon-like protein-1 
receptor agonist (GLP-1 RA) and long-acting basal 
insulin as a treatment of type 2 diabetes mellitus 
(T2DM) to achieve improved glycemic control in 
patients with T2DM is based on a solid understanding 
of the complementary physiological mechanisms of the 
actions of both agents [3]. Ample clinical data support 
combining these agents for the treatment of T2DM. It 
means an approach which is endorsed as a third-line 
treatment in the consensus report by the ADA and 
EASD on the management of hyperglycemia in     
T2DM [4].  
 
    From some large cardiovascular outcome trials 
(CVOTs), recent diabetic guidelines showed the 
recommendation of sodium-glucose cotransporter 2 
inhibitor (SGLT2i) or GLP-1RA for patients with high-
risk states of kidney disease CKD, HF, ASCVD, 
regardless of the HbA1c values [1,2]. The combined 
therapy of basal insulin plus a GLP-1RA has been one 
beneficial method to strengthen the effective treatment 
with injectable agents. By both complementary actions, 
combined agents can improve glucose variability, 
associated with the reduction of adverse effects [5,6]. 
From these, Insulin Degludec/liraglutide (IDegLira, 
Xultophy™) has been a fixed-ratio combination of 
long-acting basal insulin analog  and  also  GLP-1RA for 
 
recent therapy of T2DM [7,8]. 
 
    Our research group has been involved in clinical 
practice especially concerning diabetes, chronic renal 
failure, and hemodialysis. As regard to diabetes, 
authors and collaborators have developed research 
concerning the comparisons of low carbohydrate diet 
(LCD), calorie restriction (CR), meal tolerance test 
(MTT), increased ketone bodies, continuous glucose 
monitoring (CGM), and so on [9,10]. Furthermore, we 
established the Japan LCD Promotion Association 
(JLCDPA) and have continued various activities 
through JLCDPA such as seminars for LCD, medical 
societies, textbooks, journals, and newsletters through 
the internet [11,12].  
 
    Furthermore, for CKD and hemodialysis, we 
reported several studies concerning nerve conduction 
velocity (NCV), diabetic kidney disease (DKD), 
carnitine, and others for patients with chronic renal 
failure and hemodialysis [13,14,15]. Through our 
clinical practice, there was a case with beneficial 
efficacy with the treatment of Xultophy [16]. 
Successively, our hemodialysis team has studied the 
effect of Xultophy for hemodialysis patients, and the 
results and discussion would be described in this 
study. 
 
Subjects and Methods 
Subjects: 
    Subjects in this study included ten patients with 
T2DM and chronic renal failure (CRF) who have been 
treated by hemodialysis three times a week. The basic 
data of the subjects are shown in Table-1. 
 
Methods: 
    The purpose of the study was to administer 
Xultophy, evaluate the results, and to discuss the 
clinical significance. The patients were treated before 
by Dulaglutide or Degludec with stable diabetic state 
and stable HbA1c values. The changes in HbA1c values 
were shown in Fig-1. In this figure, #1 - #10 with 
colored numbers mean case 1 – 10 at the right side, 
and #5 - #12 with black numbers mean the starting 
doses of Xultophy at 0 months at the left side. The 
doses of them were the same or increased 1-4 doses for  
6 months. The changes in  HbA1c   on 0, 2, 4, 6 months 
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    For the current study, Xultophy includes long-acting 
insulin and GLP-1 RA. One unit of Xultophy
® 
(100/3.6) 
contains 1 unit of insulin degludec associated with 
0.036 mg of liraglutide [17]. Consequently, Xultophy 
can be injected from 10-50 units. In the case of 
Xultophy, they use 10-50 doses instead of 10-50 units.  
 
    The Xultophy
®
 pen has been prevalent, which is 
prefilled by 300 units of Xultophy® 100/3.6 (300 unit’s 
insulin degludec/10.8 mg liraglutide). As for the safety 
mechanism, it does not have a push-button extension, 
or the dose button does not move while dialing the 
doses [17]. The method is a once-daily regimen, and it 
usually has less weight gain or hypoglycemia 
associated with increased insulin regimens. In 
addition, Xultophy shows the benefit of reduced 
gastrointestinal (GI) side effects in comparison with 



























Fig-1: Changes in HbA1c of subjects for 6 months 
    Subjects include 10 diabetic patients with 
hemodialysis, in which #1 - #10 with colored numbers 
mean case 1 – 10 at right side. In contrast, #5 - #12 with 
black numbers mean the starting doses of Xultophy at 0 
months at left side.     
























1 69 M 162 58.0 22.1 5 Dulaglutide 9.9 5.9 5 
2 78 F 150 39.5 17.6 3 Dulaglutide 6.9 6.2 10 
3 68 M 172 66.0 22.3 10 Dulaglutide 10.4 6.8 12 
4 78 M 155 50.5 21.0 9 Dulaglutide 6.6 6.1 5 
5 88 F 146 36.0 16.9 11 Dulaglutide 6.5 5.6 5 
6 70 M 160 73.5 28.7 3 Dulaglutide 10.5 8.1 8 
7 71 M 165 53.0 19.5 8 Dulaglutide 8.5 7.7 10 
8 74 F 155 61.0 25.4 7 Dulaglutide 9.3 6.7 8 
9 75 M 171 48.5 16.6 3 Dulaglutide 8.4 6.0 5 
10 74 F 143 42.0 20.5 22 Degludec 4.8 6.0 6 
Mean 74.5   157.9 52.8 21.1 8.1   8.2 6.5 7.4 
SD 5.9   9.9 12.0 3.8 5.7   1.9 0.8 2.6 
  i) As previous treatment of Dulaglutide, it was administered xx mg once per week     
  ii) As previous treatment of Degludec, it was administered 6 units once per day     
  iii) Before starting Xultophy, values of creatinine and HbAic are described 
 
    
  iv) On starting treatment of Xultophy, the first doses are described in the table     
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Results 
    In the current study, the results for 10 cases of 
hemodialysis are shown in Table-1. The values of 
mean ± standard deviation (SD) were as follows: ages 
74.5 ± 5.9 years, M/F=6/4, BMI 21.1± 3.8kg/m2, 
hemodialysis duration 8.1 ± 5.7 years. The average 
value of serum creatinine before hemodialysis at 0 
months was 8.2 ± 1.9 mg/dL. By the administration of 
Xultophy, the changes in HbA1c values in 0, 2, 4, 6 
months for 10 cases were described in Fig-1. At 6 
months, 7 out of 10 showed a decreasing tendency of 




    The treatment of diabetes has changed in recent 
years. Efficient insulin preparations have emerged, and 
GLP-1 RA preparations have been introduced to clinical 
practice. Subsequently, a combination of long-acting 
insulin and GLP-1 RA has been developed.  
 
    Insulin Degludec and liraglutide are combined and it 
was approved for T2DM patients by the regulatory 
agency [19]. It was IDegLira, which is called Xultophy 
100/3.6, by Novo Nordisk, Denmark. It has been 
combined as Fixed-Ratio Combinations (FRC) of basal 
insulin and long-acting GLP-1 analog for once-daily 
subcutaneous injection for T2DM [20-22]. Its efficacy 
and safety of IDegLira have been evaluated by the 
DUAL I-IX series of randomized clinical trials (RCTs). 
They compared the new agent IDegLira use to other 
long-acting new generation basal insulin and long-
acting GLP-1 RA analog [23-25].   
 
    From these results, IDegLira was recognized to be 
superior to other agents provided alone for reducing 
HbA1c values. Furthermore, IDegLira has shown 
weight reduction rather than weight increase, reduced 
episodes of hypoglycemia, reduced insulin-dose 
requirement, and higher rates of achieving less than 
7% as HbA1c target [19-25]. These benefits were 
revealed in DUAL RCTs studies, and the beneficial 
potential of IDegLira FRC was expected for increasing 
adherence to diabetic treatment.  
 
 
    IDegLira has been produced as a fixed-ratio 
combination (FRC) of the basal degludec and 
liraglutide, GLP-1 agonist [26]. The beneficial points of 
combined agents are described [27]. From several data 
of DUAL results and post hoc analyses, some cases 
have shown remarkable efficacy for IDegLira [28]. 
Refraining from more complex injectable treatments, 
patients with renal insufficiency are one of the most 
adequate and effective cases, for whom therapeutic 
options are rather limited [28]. There is another 
research group of IDegLira, which is the European 
Xultophy Treatment Retrospective Audit (EXTRA) 
[29]. From the data of EXTRA real-world evidence 
study, better clinical outcomes and cost-effectiveness 
were observed. In detail, IDegLira vs multiple daily 
insulin injections (MDI) showed EUR 3013 vs. 6890 
per quality-adjusted life-year (QALY) gained, 
respectively. 
 
    In this study, we have tried the administration of 
IDegLira (Xultophy) in 10 hemodialysis patients and 
examined the changes in HbA1c at 0, 2, 4, and 6 
months. The protocol was successful with no particular 
problems, unexpected symptoms, or signs. 
Conventionally, it is said that no remarkable adverse 
effects are observed in the administration of Xultophy 
[26]. At 0 month, there are 5 cases with lower HbA1c 
(5.6%-6.1%), for which 5-6 doses of Xultophy were 
administered. In contrast, there are 5 cases with higher 
HbA1c (6.3%-8.1%), for which 8-12 doses of Xultophy 
were administered. At 6 months, 7 out of 10 showed a 
decreasing tendency of HbA1c, 2 showed no changes, 
and 1 showed an increasing tendency. Among them, 
the two cases with higher HbA1c at 0 months (cases 6 
and 7) showed a remarkable reduction. It was reported 
that the decrease of HbA1c was larger in the cases 
where the pre-level of HbA1c was rather higher. 
 
    As to the characteristics of the subjects in the 
current study, they are diabetic and undergoing 
hemodialysis due to chronic renal failure (CRF). 
Consequently, the relationship between renal 
dysfunction and GLP-1 RA is important. There are 
several kinds of GLP-1 Ras so far. Among them, 
lixisenatide and exenatide are predominantly cleared 
through the kidney [30]. The dose of exenatide is not 
recommended to be increased in the diabetic case  with  
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eGFR of 30–60 mL/min/1.73 m2. In contrast, 
dulaglutide and liraglutide have predominantly hepatic 
clearance. GLP-1 RAs have been recognized to show 
direct and indirect renal protective effects and some 
hepatic health benefits (Grade A; EL 1). When these are 
given to diabetic cases with renal impairment, it is 
necessary to consider the caution of gastrointestinal 
adverse effects, which is Grade D; EL 4 [30]. 
Liraglutide has shown potential vascular protective 
effects through some mechanism incompletely 
understood. From the study of T2DM rats, liraglutide 
may ameliorate vascular endothelial dysfunction via 
anti-oxidative and activated endothelial oxide synthase 
(eNOS) [31]. 
 
    This study has limitations. The subjects are patients 
undergoing hemodialysis due to diabetic renal failure, 
and their background seems to be highly 
heterogeneous. The number of cases was small, 
including mild to severe cases, and the value of HbA1c 
was distributed widely. The initial dose of Xultophy is 
reported to be 16 doses in Europe and North American 
countries, and 10 doses in Japan. In the current study, 
Xultophy was started with 5-12 doses, which were 
remarkably lower doses than usual doses with stable 
clinical course. One of the reasons may be from the 
characteristic of the patients, who were diabetic with 
undergoing hemodialysis. The provided doses of 
Xultophy were not so increased for 6 months. The 
doses will be increased according to the patient’s 
situation for better glucose variability after 6 months. 
For further investigation of the effect of IDegLira in 
hemodialysis patients, detailed studies will be required 
including adequate protocols with some groups and 
applicable biomarkers. 
 
    In summary, this pilot study showed the efficacy of 
IDegLira for diabetic patients with hemodialysis. 
Authors expect that this report would become some 




    The current study was basically conducted in 
compliance with the ethical principles. It was along 
with the Declaration of Helsinki. In addition, some 
commentary was present for the Ethical Guidelines for  
 
Research in the medical research for the human and in 
the conduction of the Good Clinical Practice (GCP). 
Regarding the protection of human rights, some 
ongoing consideration was present. Further, there was 
“Ethical Guidelines for Epidemiology Research” 
applied for the related guideline. Those principles were 
from Japan by the Ministry of Health, Labor and 
Welfare, and the Ministry of Education, Culture, 
Sports, Science, and Technology. 
 
    As to this study, authors have taken the written 
informed consent from all subjects. Moreover, we 
established the ethical committee in Kanaiso hospital 
for clinical research. The ethical committee includes 
the president of the hospital, the director of the 
Pharmacology Department, the directors of the 
nursing and administration departments, and some 
experts in the legal, medical, and pharmaceutical 
specialties. The members discussed satisfactory about 
the research content and agreed that this study would 
be adequate without any problems.  
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